Coronavirus company news summary - Australia clears SpeeDx's single-well SARS-CoV-2 test - Quest and eMed launch Covid-19 rapid antigen testing for US employers - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Australia clears SpeeDx’s single-well SARS-CoV-2 test – Quest and eMed launch Covid-19 rapid antigen testing for US employers

12 Aug 2021

SpeeDx has obtained clearance from the Australian Therapeutic Goods Administration for its two-gene PlexPCR SARS-CoV-2 test to identify all presently circulating variants of the virus. The single-well test is developed using a database of more than one million sequences. It combines automated software reporting and SpeeDx PlexPrep liquid handling robotics to enable throughputs of 480 to 1,920 patient samples in eight hours.

Quest Diagnostics has partnered with telehealth provider eMed to facilitate clinician-guided rapid antigen Covid-19 testing for employers to mitigate exposure risk at workplaces in the US. The partners will use the BinaxNOW COVID-19 Ag Card Home Test, a self-test that analyses nasal swabs and delivers results in 15 minutes. A certified guide from eMed will oversee the testing virtually. Employees travelling abroad can use the antigen test during their trip for returning to the US.

Biotech firm Aditxt has collaborated with Great Lakes Medical Laboratory (GLML) to launch AditxtScore for COVID-19, an immune response monitoring tool, in Michigan, US. The new solution is designed to detect a spectrum of biomarkers linked to the infection. It monitors several combinations of antibody and neutralising antibody responses to various antigens, thereby allowing analysis of a person’s immune response against SARS-CoV-2. GLML will offer AditxtScore at its six physical locations and mobile units in the state.